REDWOOD CITY, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it will present new and emerging data from its most advanced clinical programs at the upcoming European Society for Medical Oncology (ESMO) 2014 Congress to be held September 26-30, 2014 in Madrid, Spain.
At this year's ESMO Congress, OncoMed will have a total of four poster and poster discussion presentations. Presenting authors will share data from Phase 1b clinical trials of demcizumab (anti-DLL4, OMP-21M18) and tarextumab (anti-Notch 2/3, OMP-59R5). Data from the Phase 1b studies will inform the company's planned randomized Phase 2 clinical trials of demcizumab in non-small cell lung cancer and pancreatic cancer and tarextumab in small cell lung cancer. OncoMed initiated the Phase 2 portion of the ALPINE clinical study of tarextumab in pancreatic cancer earlier this year. The list of abstracts and timing of the presentations is provided below.
|September 27, 2014 - 12:45 pm -1:45 pm|
|1. Demcizumab: "A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM), Pemetrexed (PEM) & Carboplatin (CARBO) in Patients with First-line Non-Squamous NSCLC." (#1240P)|
|Presenting author: Robert Stagg, Pharm D, OncoMed Pharmaceuticals|
|Poster Display Session|
|September 28, 2014 - 12:45 pm -1:45 pm|
|2. Demcizumab: "A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM) & Gemcitabine (GEM) +/-- Paclitaxel Protein Bound Particles (nab-paclitaxel) in Patients with Pancreatic Cancer."(#616PD|
|Presenting author: Manuel Hidalgo, M.D., Ph.D., CNIO-CIOCC-START|
|Poster Discussion Session|
|September 29, 2014 - 12:45 pm - 1:45 pm|
|3. Tarextumab: "Final Results of a Phase 1b of OMP-59R5 (anti-Notch2/3/stem cell antibody) in Combination with Nab-paclitaxel and Gemcitabine (Nab-P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Study" (#688P)|
|Presenting author: Johanna Bendell, M.D., Sarah Cannon Research Institute|
|Poster Display Session|
|4. Tarextumab: "Phase 1b Trial of anti-Notch 2/3 Antibody OMP-59R5 in Combination with Etoposide and Cisplatin (EP) in Patients (pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (ED-SCLC): the PINNACLE Study" (#1473P)|
|Presenting author: M. Catherine Pietanza, M.D., Memorial Sloan Kettering Cancer Center|
|Poster Display Session|
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development, anti-DLL4/anti-VEGF bispecific (OMP-305B83) and anti-RSPO3 (OMP-131R10), with Investigational New Drug filings planned for late 2014 or early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding OncoMed Pharmaceuticals, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including OncoMed's expectations regarding the advancement of demcizumab into randomized Phase 2 clinical trials in non-small cell lung cancer and pancreatic cancer; the advancement of tarextumab into a randomized Phase 2 clinical trial in small cell lung cancer; and the timing of Investigational New Drug filings for OncoMed's anti-DLL4/anti-VEGF bispecific and anti-RSPO3 antibodies. Such forward-looking statements involve substantial risks and uncertainties that could cause OncoMed's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; OncoMed's dependence on its collaboration partners, including Celgene, GSK and Bayer, for the funding of its partnered programs; OncoMed's ability to raise additional capital to support the development of its unpartnered programs; OncoMed's dependence on the development and marketing efforts of its partners for the commercial success of its partnered product candidates; OncoMed's reliance on third parties to conduct certain preclinical studies and all of its clinical trials; OncoMed's reliance on single source third-party contract manufacturing organizations to manufacture and supply its product candidates; OncoMed's ability to validate, develop and obtain regulatory approval for companion diagnostics; OncoMed's ability to achieve market acceptance and commercial success of its product candidates once regulatory approval is achieved; OncoMed's ability to discover, develop and commercialize additional product candidates; the ability of competitors to discover, develop or commercialize competing products more quickly or more successfully; OncoMed's dependence on its Chairman and Chief Executive Officer, its Chief Scientific Officer, its Chief Medical Officer and other key executives; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate OncoMed's patents or proprietary rights; and the ability of OncoMed's proprietary rights to protect its technologies and product candidates. OncoMed undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to OncoMed's business in general, see OncoMed's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the Securities and Exchange Commission (SEC) on March 18, 2014, OncoMed's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2014, filed with the SEC on May 8, 2014,and OncoMed's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2014, filed with the SEC on August 7, 2014.
CONTACT: Investor Contact: OncoMed Pharmaceuticals Shari Annes Investor Relations (650) 888-0902 email@example.com Media Inquiries: BCC Partners Michelle Corral or Karen L. Bergman (415) 794-8662 or (650) 575-1509 firstname.lastname@example.org or email@example.com
Source:OncoMed Pharmaceuticals, Inc.